GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals

More

  • Cramer's Mad Dash: Finish Line's victory lap Friday, 26 Jun 2015 | 9:22 AM ET
    Cramer's Mad Dash: Finish Line's victory lap

    Jim Cramer says Finish Line posted a winning quarter and Alder Biopharma will determine the face of biotech.

  • Kite Pharma CEO: Targeting cancer cells Wednesday, 24 Jun 2015 | 7:52 AM ET
    Kite Pharma CEO: Targeting cancer cells

    Arie Belldegrun, Kite Pharma CEO, discusses the future of immunotherapy and its collaboration to develop cancer T-cell therapies.

  • Inside Kite Pharma's 100% run Wednesday, 24 Jun 2015 | 7:51 AM ET
    Inside Kite Pharma's 100% run

    CNBC's Meg Tirrell takes a look at what's driving shares of Kite Pharma higher, as the biotech company announces it is joining forces with Bluebird to collaborate on cancer T-cell therapies.

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • FDA approves new Medtronic's heart valve device Tuesday, 23 Jun 2015 | 3:29 PM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    The CEO of Medtronic talks new FDA approval and how to improve the health-care system.

  • Genetic based testing, growth area for us: DGX CEO Tuesday, 23 Jun 2015 | 1:15 PM ET
    Genetic based testing, growth area for us: DGX CEO

    Steve Rusckowski, Quest Diagnostics CEO, sits down with CNBC's Meg Tirrell for an exclusive interview.

  • Great time for Boston Scientific: CEO Tuesday, 23 Jun 2015 | 12:32 PM ET
    Great time for Boston Scientific: CEO

    CNBC's Meg Tirrell sits down with Michael Mahoney, Boston Scientific CEO, for an exclusive interview.

  • Excited about new product: Medtronic CEO Tuesday, 23 Jun 2015 | 11:39 AM ET
    Excited about new product: Medtronic CEO

    CNBC's Meg Tirrell sits down with Omar Ishrak, Medtronic CEO, for an exclusive interview to discuss the company's product pipeline and business strategy.

  • Charts: Biotech bull market intact, buy this ETF Monday, 22 Jun 2015 | 9:18 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Chart analyst John Kosar explains why biotech stocks have further to run, despite recent weakness.

  • Business of bacteria Friday, 19 Jun 2015 | 3:46 PM ET
    Business of bacteria

    Johnson & Johnson has established a microbiome institute to focus on developing treatments aimed at restoring the balance of micro-organisms. Details, with CNBC's Meg Tirrell.

  • Biotech bargain bin Friday, 19 Jun 2015 | 3:44 PM ET
    Biotech bargain bin

    CNBC's Morgan Brennan finds bargains in the outperforming biotech sector.

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Biotechs about to break out: Pro Friday, 19 Jun 2015 | 1:41 PM ET
    Biotechs about to break out: Pro

    Michael Yee, RBC Capital Markets, biotech analyst, discusses growth to come in the biotech sector and forecasts if the all-time highs will continue. Also, which stocks to own in the space.

  • Microbiome studies changing human health Friday, 19 Jun 2015 | 8:33 AM ET
    Microbiome changing human health

    CNBC's Meg Tirrell explains what the microbiome is and why it's medicines new frontier.

  • Medicine's next frontier: The microbiome Friday, 19 Jun 2015 | 8:30 AM ET
    Bacteria illustration

    Fecal microbiota transplantation. It's exactly what it sounds like. And for patients such as Natalie Gurvich, it can seem like a miracle cure.

  • Biotech breakout to last? Thursday, 18 Jun 2015 | 3:25 PM ET
    Biotech breakout to last?

    Where the biotech sector is headed, with Rich Ross of Evercore ISI.

  • Botox-maker gets business facelift Wednesday, 17 Jun 2015 | 8:41 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Botox-maker Allergan Plc said it would buy Kythera Biopharmaceuticals Inc in a deal to expand its line of cosmetic treatments.

  • $180 million discovery from the placenta Wednesday, 17 Jun 2015 | 6:50 AM ET
    $180 million discovery from the placenta

    Biotech MiMedx sells amniotic membrane tissue that is used to help wounds heal 2-3 times faster than standard care. MiMedx CEO Pete Petit, discusses the effective tissue developed from the placenta.

  • Your drug prices too high? Here's who many blame Tuesday, 16 Jun 2015 | 3:00 AM ET
    Pharmaceuticals

    Americans place controlling drug costs at the top of their health-related concerns.

  • UTHR CEO: Future of biotech Monday, 15 Jun 2015 | 4:25 PM ET
    UTHR CEO: Future of biotech

    CNBC's Meg Tirrell speaks to Martine Rothblatt, United Therapeutics CEO about the future of transplants and near-term RNA techniques.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.